Xinlitai disrupted the market of antiepileptic drugs, and levetiracetam tablets passed the consistency evaluation

On November 2, Shenzhen xinlitai released the enterprise announcement: Recently, Shenzhen xinlitai Pharmaceutical Co., Ltd (hereinafter referred to as "the company") received the approval document of drug supplement application of levetiracetam tablets (0.25g) approved and issued by the State Drug Administration, which passed the consistency evaluation of quality and efficacy of generic drugs Levetiracetam tablets (XINTONGAN ®) are used for the treatment of partial seizures (with or without secondary generalized seizures) in adults and children over 4 years old, and for the treatment of generalized tonic clonic seizures in adults and adolescents over 16 years old Zuelacetan tablets belong to the class B products of national medical insurance, and it is one of the drugs purchased intensively by the state Levetiracetam is a new antiepileptic drug with new antiepileptic mechanism, which was first developed by UCB company in Belgium According to the hospital sales data of pharmaceutical intelligence data Enterprise Edition, the sales of domestic sample hospitals are almost all occupied by the original research enterprises In 2018, the sales volume of sample hospitals reached 84.563 million yuan It is particularly noted that since zuelacetan tablet belongs to the drug centralized procurement, in September this year, in the announcement of the proposed bid winning results of the drug centralized procurement expansion, only Zhejiang Jingxin pharmaceutical and Zhejiang puluokangyu pharmaceutical, which have been evaluated for consistency, have won the bid Therefore, the impact on the original research will be further increased, and with the increasing More and more enterprises have passed the consistency evaluation of this variety, so it is not impossible for domestic generic drugs to replace the original research At present, the domestic enterprises that have passed or are deemed to have passed the consistency evaluation include Zhejiang Jingxin Pharmaceutical Co., Ltd., Zhejiang puluokangyu Pharmaceutical Co., Ltd and China Resources SECCO Pharmaceutical Co., Ltd Zhejiang puluokangyu Pharmaceutical Co., Ltd and China Resources SECCO are approved for production by virtue of the registration classification of new chemical drugs, which are deemed to have passed the consistency evaluation Now, xinlitai Pharmaceutical Co., Ltd is the fourth enterprise that has passed the consistency evaluation, breaking the situation of tripartite confrontation and joining the war In addition, according to the announcement, xinlitai has two dosage forms of zuelacetan tablets and sustained-release zuelacetan tablets At present, through the consistency evaluation, xinlitai has provided more options for patients, improved their long-term medication compliance, improved the comprehensive competitiveness of products, and had a positive impact on the company's performance improvement Information source: and announcement 37 of the enterprise: This article is the integration content, and the viewpoint only represents the author, not the position of Welcome to exchange and supplement in the message area If you need to reprint, please be sure to indicate the author and source of the article.